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Objective: We aimed to compare the outcomes of in vitro fertilization/intracytoplasmic sperm injection
(IVF/ICSI) treatments in women of advanced age (>40 years) using anti-Müllerian hormone (AMH)-
tailored ovarian stimulation protocols versus conventional protocols based on antral follicle count (AFC).
Materials and Methods: We retrospectively reviewed 210 women who underwent IVF/ICSI cycles: 116
women underwent stimulation protocols that were tailored to their AMH levels, whereas 94 women
received treatment using conventional stimulation protocols based on AFC as the ovarian reserve marker.
Results: The following parameters were signiﬁcantly higher in the AMH-tailored group than in the
conventional group: initial and total doses (IU) of recombinant follicle-stimulating hormone (rFSH) used
for stimulation (514.2 ± 137.9 vs. 452.3 ± 135.3, p ¼ 0.001; 4713.8 ± 1618.8 vs. 4047.2 ± 1366.0, p ¼ 0.007,
respectively), ovum pick-up rate (OPU; 88.8% vs. 75.5%, p ¼ 0.016), serum estradiol (E2) level on the day
of human chorionic gonadotropin (hCG) administration (1818.5 ± 1422.4 vs. 1394.0 ± 929.0 pg/mL,
p ¼ 0.028), number of oocytes retrieved (7.4 ± 5.1 vs. 5.5 ± 3.4, p ¼ 0.007), number of embryos per case
(4.2 ± 3.2 vs. 3.3 ± 2.5, p ¼ 0.048), clinical pregnancy rates (22.4% vs. 8.5%, p ¼ 0.008), implantation rates
(13.1% vs. 3.9%, p ¼ 0.001), and live birth rates per cycle (15.5% vs. 6.4%, p ¼ 0.049).
Conclusion: Individualized controlled ovarian stimulation (COS) protocols tailored to patients' AMH
levels may improve the pregnancy rate, implantation rate, and live birth rate in women of advanced age
undergoing IVF/ICSI compared with those receiving conventional stimulation protocols.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein pro-
duced by the granulosa cells of preantral and antral ovarian folli-
cles. In the past, AMH has played a signiﬁcant role in infertility
assessment and treatment because it is a more accurate marker for
predicting ovarian response to controlled ovarian stimulation (COS)n N. Rd., Taipei City 10449,
wu).
bstetrics & Gynecology. Published bthan age or levels of Day 3 follicle-stimulating hormone (FSH),
estradiol (E2), and inhibin B [1e3]. Before in vitro fertilization/
intracytoplasmic sperm injection (IVF/ICSI) treatments are initi-
ated, AMH levels can help guide clinicians in counseling their pa-
tients about the risks and beneﬁts of treatment and the likelihood
of success, as well as allowing them to individualize treatment
strategy according to the anticipated ovarian reserve. AMH levels
are also correlated with the onset of menopause; however, its value
is much more limited in the accurate prediction of the age of
menopause [4]. In several reviews and meta-analyses, AMH mea-
surement prior to ovarian stimulation has been associated with
accurate prediction of ovarian over-response; therefore, choosing ay Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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patient's serum AMH level may help reduce the incidence of
ovarian hyperstimulation syndrome (OHSS) [1e3,5,6]. However,
the utility of AMH levels for predicting poor ovarian response has
been questioned, and evidence supporting the role of AMH in
predicting pregnancy outcomes is scarce [5e7]. Thus, the aim of
this study was to compare the outcomes of IVF/ICSI between
women of advanced age using AMH-tailored stimulation protocols
and conventional stimulation protocols based on antral follicle
count (AFC) as the ovarian reserve marker.Material and methods
Study participants
We retrospectively reviewed and analyzed the medical records
of all patients aged > 40 years who received IVF/ICSI treatment at
the Infertility Division of the Department of Obstetrics and Gyne-
cology at MacKay Memorial Hospital in Taipei, Taiwan, between
January 1, 2006 and September 30, 2011. The study protocol was
approved by the Institutional Review Board of MacKay Memorial
Hospital. The inclusion criteria for the reference population were
patients who underwent a cycle of IVF, with or without ICSI, using
fresh embryos, during the study period. The exclusion criteria were
the presence of any of the following conditions: (1) infertility due to
a uterine factor (e.g., thin endometrium, endometrial synechiae);
(2) cancer; and (3) systemic disease (e.g., diabetes mellitus, thyroid
disease, autoimmune disease).Study design
Participants were divided into two groups according to the
availability of AMH data. The control group comprised womenwho
were treated with a conventional protocol of ovarian stimulation
using chronological age and AFC as markers of the ovarian reserve,
because AMH data was not obtained prior to beginning ovarian
stimulation. The starting dose of gonadotropins for the control
group was determined according to AFC with a baseline dose of
450 IU if AFC  5 or decrease dose to 150 IU if AFC > 15.
The average time required to receive AMH level test results in
our hospital is 2 weeks; therefore, AMH data for women in the
control group was usually not obtained due to the time constraints
of patients who live far away from the hospital or abroad, or who
did not have a chance to obtain an AMH-level test prior to initiating
treatment. The study group consisted of women whose basal AMH
levels were measured within 3 months prior to treatment, and
whose starting dose of gonadotropins was tailored to their serum
levels of AMH of those < 1.0 receiving a 600-IU dose of FSH, those
1.0 and < 1.2 receiving a 525-IU dose of FSH, those  1.2 and < 1.5
receiving a 450-IU dose of FSH, those 1.5 and < 2 receiving a 300-
IU dose of FSH, those  2 and < 5 receiving a dose of 225-IU, and
those  5 receiving a dose of 150 IU.
Poor response to ovarian stimulation, which resulted in cycle
cancelation, was deﬁned as a serum E2 level of  500 pg/mL and 
two follicles > 16 mm seen on transvaginal ultrasonography on the
day of human chorionic gonadotropin (hCG) administration. The
main outcomes compared included the initial dose of recombinant
FSH (rFSH), total dose of rFSH, duration of stimulation, serum E2
level on hCG day, ovum pick-up (OPU) rate, number of oocytes
retrieved, number of embryos per case, embryo transfer (ET) rate,
number of embryos transferred, clinical pregnancy rate, implan-
tation rate, live birth rate, and abortion rate of women receiving
AMH-tailored stimulation protocols and those undergoing con-
ventional stimulation protocols.COS
Pelvic ultrasonography was used to check for pelvic cavity ab-
normalities, including ovarian tumors, on Day 2e3 of themenstrual
cycle. Patients underwent IVF treatment using a long down-
regulation or short ﬂare-up protocol with a gonadotropin-releasing
hormone (GnRH) agonist or GnRH antagonist protocol. In the GnRH
agonist protocol, pituitary suppression was initiated with 1 mg
subcutaneous leuprolide acetate (Takeda Pharma GmbH, Stolberg,
Germany) beginning on Day 21 of the previous menstrual cycle
until the serum levels of E2 fell below 30 pg/mL, and thereafter
0.5 mg leuprolide acetate until hCG day. In the GnRH antagonist
protocol, 0.25 mg subcutaneous cetrorelix (Cetrotide; Serono,
Baxter Oncology GmbH, Halle, Germany) or 0.25 mg ganirelix ac-
etate (Orgalutran; Schering-Plough, Whitehouse Station, NJ, USA)
was administered daily when the follicles were > 14 mm in
diameter until hCG day. All patients received rFSH (Gonal-F; Serono
Laboratories, Aubonne, Switzerland) and/or human menopausal
gonadotropin (Menopur; Ferring GmbH, Kiel, Germany). The
dosage of gonadotropin was determined by the age of the patient
and the AFC or the AMH levels. The dosagewas then adjusted every
2e3 days in accordancewith follicle growth.When a leading follicle
 18mm in diameter was detected by ultrasonography,10,000 IU of
hCG (Pregnyl; Schering-Plough, Kenilworth, NJ, USA) or 250 mg of
choriogonadotropin-alfa (Ovidrel; Serono, Rome, Italy) was
administered, and oocyte retrieval was performed 34e36 hours
later. We performed IVF or ICSI with either ejaculated sperm or
surgically retrieved sperm. Up to four embryos were transferred
into the uterine cavity on Day 2e3 after oocyte retrieval according
to the embryo number and quality. Clinical pregnancy was deﬁned
as the presence of an intrauterine gestational sac by ultrasonog-
raphy at approximately 5 weeks of pregnancy.
Serum AMH measurement
AMH levels were measured by enzyme-linked immunosorbent
assay kit (Diagnostic Systems Laboratories, Webster, TX, USA). The
detection range of the assay was 0.025e15 ng/mL, with the detec-
tion limit at 0.017 ng/mL. Values below the detection limit were
considered zero. The intra-assay and interassay variation co-
efﬁcients were 4.6% and 8.0%, respectively. Samples from all par-
ticipants were obtained via venipuncture and analyzed by the same
laboratory (Department of Immunoassay, MacKay Memorial Hos-
pital, Taipei, Taiwan). The samples were processed according to the
manufacturer instructions by centrifuging at 1400g for 10 minutes
to separate cellular contents and debris; the serum was then
transferred to sterile polypropylene tubes to be preserved at 70C
until the assay.
Statistical analysis
The main outcome measures were compared using the Chi-
square test or Fisher exact test for comparing percentages and a t
test for comparing mean values. Statistical analyses were per-
formed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A p
value  0.05 was considered statistically signiﬁcant for all
measures.
Results
After applying inclusion and exclusion criteria, 210 patients
were included; of them, 116 patients comprised the study group
(i.e., the AMH-tailored group), whereas 94 patients comprised the
control group (i.e., the conventional stimulation group). Table 1
summarizes their characteristics.
Table 1
Characteristics of anti-Müllerian hormone (AMH)-tailored ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles inwomen of advanced
age (> 40 years).
AMH-tailored group Conventional stimulation group p
No. of cases 116 94
Causes of infertility
1. Male factor 33 (28.4) 30 (31.9) 0.522
2. Tubal factor 31 (26.7) 21 (22.3) 0.65
3. Endometriosis 18 (15.5) 8 (8.5) 0.144
4. Ovulation dysfunction 15 (12.9) 24 (25.5) 0.021
5. Other 19 (16.4) 11 (11.7) 0.428
AMH level (ng/mL), mean ± SD 1.79 ± 1.51 d d
Use of ICSI 56 (48.3) 35 (37.2) 0.124
Data are presented as n (%) unless otherwise indicated.
ICSI ¼ intracytoplasmic sperm injection; SD ¼ standard deviation.
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in the number of cases with ovulation dysfunction, which was
signiﬁcantly higher in the conventional stimulation group
(p¼ 0.021). Table 2 shows the outcomes in the AMH-tailored group
and conventional stimulation group. The initial dose of rFSH
selected and the total dose of rFSH usedwere signiﬁcantly higher in
the AMH-tailored group than in the conventional stimulation group
(514.2 ± 137.9 IU vs. 452.3 ± 135.3 IU, p ¼ 0.001 and
4713.8 ± 1618.8 IU vs. 4047.2 ± 1366.0 IU, p ¼ 0.007). The following
parameters were also signiﬁcantly higher in the AMH-tailored
group: OPU rate (88.8% vs. 75.5%, p ¼ 0.016), serum E2 level on
the day of hCG administration (1818.5 ± 1422.4 pg/mL vs.
1394.0 ± 929.0 pg/mL, p ¼ 0.028), number of oocytes retrieved
(7.4 ± 5.1 vs. 5.5 ± 3.4, p ¼ 0.007), number of embryos per case
(4.2 ± 3.2 vs. 3.3 ± 2.5, p¼ 0.048), clinical pregnancy rates (22.4% vs.
8.5%, p ¼ 0.008), implantation rates (13.1% vs. 3.9%, p ¼ 0.001), and
live birth rates per cycle (15.5% vs. 6.4%, p ¼ 0.049). There were no
signiﬁcant differences in the duration of stimulation, ET rate,
number of transferred embryos per ET, and the abortion rate be-
tween the two groups.Discussion
Individualization of IVF treatment allows clinicians to manage
infertile women according to their unique characteristics; thisTable 2
Outcomes of anti-Müllerian hormone (AMH)-tailored ovarian stimulation in in vitro fertil
(> 40 years).
AMH-tailored group
No. of cases 116
Initial rFSH dose/d
(IU)
514.2 ± 137.9
Total rFSH dose
(IU)
4713.8 ± 1618.8
Stimulation day 10.2 ± 2.0
E2 level on trigger day
(pg/mL)
1818.5 ± 1422.4
OPU rate (%) 88.8
Cycle cancellation rate (%) 11.2
Embryo no./case 4.2 ± 3.2
Transferred embryo no./case 3.1 ± 1.1
Embryo transfer rate (%) 75.9
Clinical pregnancy rate/cycle (%) 22.4
Implantation rate (%) 13.1
Abortion rate (%) 26.9
Ectopic pregnancy rate (%) 3.8
Live birth rate/cycle (%) 15.5
Data are presented as mean ± SD or %, unless otherwise indicated.
E2 ¼ estradiol; OPU ¼ ovum pick-up; rFSH ¼ recombinant follicle-stimulating hormonewould ideally maximize the clinical pregnancy rate, reduce iatro-
genic risks such as OHSS, andminimize the risk of cycle cancelation.
In particular, the ability to predict an individual patient's ovarian
response to stimulation is very useful for selecting a gonadotropin
dosage that is likely to be both effective and safe. The decision
making is usually empirical and based on the clinician's preference,
if no previous cycle has been performed [8].
Serum AMH levels seem to be a better marker for predicting
ovarian response to COS than either patient age or serum levels of
FSH, E2, and inhibin B. In the clinical setting, the intercycle and
intracycle variability in serum AMH levels is considered low
enough to permit random timing of AMH measurement during the
menstrual cycle [1e3,9e11]. While AFC is also a useful marker of
ovarian response to COS [2,12], it may be a less reliable measure due
to two logistical factors: (1) the limited window of time inwhich to
perform ultrasonographic evaluations of antral follicles; and (2) the
variable skills of the operators performing the baseline evaluations.
Several studies have indicated the potential beneﬁts of using
AMH to individualize treatment strategies for COS. Nelson et al [6]
reported a prospective cohort study of 538 patients in two centers
with differential COS strategies based on a centralized AMH mea-
surement. Their results showed that the use of circulating AMH
levels to individualize treatment strategies for COS may result in
reduced clinical risk, optimized treatment burden, and improved
pregnancy rates; however, the investigators stated that furtherization/intracytoplasmic sperm injection (IVF/ICSI) cycles in women of advanced age
Conventional stimulation group p
94
452.3 ± 135.3 0.001
4047.2 ± 1366.0 0.007
10.1 ± 2.3 0.824
1394.0 ± 929.0 0.028
75.5 0.016
24.5 0.016
3.3 ± 2.5 0.048
2.9 ± 1.3 0.293
66.0 0.126
8.5 0.008
3.9 0.001
12.5 0.645
12.5 0.421
6.4 0.049
; SD ¼ standard deviation.
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ings. Moreover, the results of the present study are supported by
those of a recent large retrospective study by Yates et al [7]. They
evaluated 769 women aged < 40 years undergoing a ﬁrst cycle of
IVF using fresh embryos, and found that women who received
individualized AMH-tailored COS protocols had signiﬁcantly higher
rates of fertilization, ET, pregnancy, and live birth than those who
underwent conventional stimulation protocols. Furthermore,
tailoring stimulation protocols to AMH levels decreased the inci-
dence of adverse outcomes such as OHSS and failed fertilization,
and reduced the ﬁnancial burden associated with assisted repro-
duction. Unfortunately, the patients in each group of the studywere
not treated during the same period of time, and therefore the
outcomes of these IVF cycles may have varied simply because the
quality and performance of IVF management improved with time.
Arce et al [13] also noted a positive association between serum
AMH concentrations and the clinical outcome in fresh IVF cycles.
They collected data from 749 women, aged 21e34 years, with a
primary diagnosis of unexplained infertility or mild male factor
infertility, who had serum FSH levels of 1e12 IU/L and AFC 10 in a
GnRH antagonist cycle with compulsory single-blastocyst transfer.
When comparing patients with AMH levels above and below the
50th percentile, both the ongoing pregnancy rate (32% vs. 23%,
p ¼ 0.006) and the live birth rate (31% vs. 23%, p ¼ 0.022) were
signiﬁcantly higher in patients with high AMH levels. The positive
association between AMH levels and clinical outcomes reﬂected
the strong correlationwith oocyte yield and the availability of more
oocytes and more embryos, at least in younger patients. In the
present study, the study population comprised women of advanced
age from the same period of time. To the best of our knowledge,
ours is the ﬁrst study to report the outcomes of AMH-tailored
stimulation protocols in women aged > 40 years.
A key factor determining the outcome of COS is the selection of
the starting dose of gonadotropin. The need for individualizing
gonadotropin dosage derives from the assumption that variability
in the functional ovarian reserve and the pool of recruitable follicles
is very wide; thus, a standard ﬁxed dose of gonadotropin may not
be suitable for all cases [8]. Lee et al [14] reported that women
aged > 40 years with an AMH concentration in the middle third
(0.49~1.22 ng/mL) or upper third ( 1.23 ng/mL) had increased
clinical pregnancy rates, decreased cycle cancelation rates, and
increased numbers of eggs retrieved and embryos transferred than
women in the lower third ( 0.48 ng/mL). We speculate that
increasing the starting gonadotropin dosage used in patients in the
lower andmiddle thirds of AMH concentration might have resulted
in improved clinical pregnancy rates comparable with those in the
upper third.
In the present study, the mean initial dose of rFSH and the mean
total dose of rFSH were both signiﬁcantly higher in the AMH-
tailored stimulation group. We supposed that AFC and AMH were
both better ovarian reserve markers. Initially, we only used AFC for
initial dose adjustment; a wide variation by different ultrasound
operators and miscalculation happened often. Thus, there may be
better results from the use of higher doses of gonadotropins in the
AMH-tailored group because of the better estimated ovarian
reservation evaluation, and this prevents the possibility of unjus-
tiﬁed gonadotropin doses. We increased the starting dose and total
dose of rFSH in patients with relatively lower levels of AMH with
the goal of stimulating more follicles for oocyte retrieval and thus
reducing cycle cancelation rates. We calculated the clinical preg-
nancy rate after excluding the cancellation cases, and it still
remained the trendwith the better clinical pregnancy rates of 25.2%
versus 11.3%, p ¼ 0.031 in the study group. Our results indicated
that the OPU rate, serum E2 level on trigger day, number of oocytes
retrieved, and number of embryos per case were also signiﬁcantlyhigher in the AMH-tailored stimulation group. Because a greater
number of embryos developed overall, the chances of obtaining
high-quality embryos to transfer were improved. These outcomes
were also associated with a signiﬁcantly improved clinical preg-
nancy rate, implantation rate, and live birth rate per cycle inwomen
aged > 40 years who underwent an AMH-tailored stimulation
protocol.
It is our limitation that the small sample size (n¼ 210) of women
aged > 40 years undergoing IVF treatment and the retrospective
design cannot make a conclusive treatment guideline. The high
incidence of ovulation dysfunction in the conventional group may
also have a selection bias. In the future, particularly when targeting
only a speciﬁc group of the population with infertility, a larger
sample size and a prospective, randomized controlled designwould
be preferable.
Ovarian reserve marker assessment, such as AMH and AFC, al-
lows clinicians to set expectations for an individual patient's
ovarian response to gonadotropins and to adjust ovarian stimula-
tion strategies accordingly. The study results in the AMH-tailored
group, an increased starting dose and total dose of rFSH in pa-
tients with relatively low levels of AMH, might help to stimulate
more follicles and, consequently, reduce cycle cancelation rates and
increase serum E2 levels and the number of oocytes retrieved. In
turn, a higher number of oocytes yielded a greater number of
embryos to select from and transfer. Thus, individualized COS
protocols tailored by AMH level ultimately may improve clinical
outcomes such as pregnancy rate, implantation rate, and live birth
rate in women of advanced age.
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